Hématologie
MENUNew-generation sequencing (NGS) in hematologic oncology laboratories Volume 19, issue 2, Mars-Avril 2013
Figures
Alice Marceau-Renaut, Aline Renneville, Olivier Nibourel, Olivia Jardin-Mathé, Christophe Demay, Céline Villenet, Sandrine Geffroy, Nathalie Helevaut, Sabine Quief, Chadi Saad, Nathalie Grardel, Aurélie Caillault, Nicolas Duployez, Thomas Boyer, Christophe Roumier, Frédéric Leprêtre, Meyling Cheok, Nicole Porchet, Martin Figeac, Claude Preudhomme
Laboratoire d’hématologie cellulaire,
centre de biologie-pathologie,
CHRU Lille, Unité Inserm 837 équipe 3,
Institut de recherche sur le cancer de Lille, Plateforme génomique fonctionnelle et structurale,
Institut de recherche sur le cancer de Lille, Laboratoire de biochimie,
centre de biologie-pathologie,
CHRU Lille
- Key words: NGS, resequencing, leukemia, mutation, bioinformatics
- DOI : 10.1684/hma.2013.0792
- Page(s) : 112-22
- Published in: 2013
New-generation sequencing (NGS) is a true technological leap forward. Although the first applications have mainly focused on whole-genome sequencing intended to identify new gene mutations, it is appearing today in hospital laboratories as an approach to targeted resequencing. Hospital applications in hematologic oncology are currently being transferred to this technology, with numerous advantages but also some constraints. The objective of this review to take an inventory of NGS in our discipline at the beginning of 2013.